SASLT practice guidelines for the management of Hepatitis B virus – An update

Abaalkhail, Faisal; Al–Hamoudi, Waleed; Khathlan, Abdullah Al; Alghamdi, Saad; Alghamdi, Mohammed; Alqahtani, Saleh A.; Sanai, Faisal M.

doi:10.4103/sjg.sjg_539_20

Cited by 13 publications

(28 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HBcAg is generally not detectable in the serum, while HBcAb can be detected. High titers of core antibodies indicate that the hepatitis B virus is replicating and infectious and persists for years to decades, while low titers of core antibodies indicate the previous infection with the hepatitis B virus [ 38 ].…”

Section: Discussionmentioning

confidence: 99%

Application Effect and Accuracy Analysis of Electrochemiluminescence Immunoassay and Enzyme-Linked Immunosorbent Assay in the Serological Test of Hepatitis B Virus

Lian

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To explore the validity and accuracy of electrochemiluminescence immunoassay (ECLIA) and enzyme-linked immunosorbent assay (ELISA) in the serological detection of the hepatitis B virus. Methods. From 6 February 2019 to 1 March 2020, 96 patients diagnosed with hepatitis B virus infection in our hospital were recruited and assigned at a ratio of 1 : 1 to experimental groups A (GA) and B (GB), with 48 cases in each group, and the five major serological indicators of hepatitis B were tested and analyzed using ECLIA and ELISA. In addition, 50 suspected patients were selected for two tests, respectively, to compare the accuracy of the two test methods. Results. ECLIA was associated with significantly higher expression levels and higher detection rates of HBeAg, HBeAb, HBsAg, and HBsAb versus ELISA ( P < 0.05 ), and the difference in the expression and detection rates of HBcAb levels between the two groups did not come up to the statistical standard ( P > 0.05 ). ECLIA yielded significantly higher sensitivity and specificity than ELISA ( P < 0.05 ), while the two methods showed comparable detection accuracy ( P > 0.05 ). Conclusion. Despite the inconsistent results of the latest studies on the serological detection of hepatitis B by the two techniques, ECLIA is consistently superior to ELISA and provides better diagnostic benefits and merits promotion.

show abstract

Section: Discussionmentioning

confidence: 99%

Application Effect and Accuracy Analysis of Electrochemiluminescence Immunoassay and Enzyme-Linked Immunosorbent Assay in the Serological Test of Hepatitis B Virus

Lian

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…At‐risk groups should also be prioritised for health education, including on the benefits of screening 2 . Continuing education programs and awareness campaigns are important, as well as the development and adaptation of regional clinical practice guidelines 8 . The role of primary care physicians, the implementation of community‐based initiatives and the role of civil society in HBV education, prevention, diagnosis and management are also key considerations.…”

Section: Move Hbv Out Of the Shadowsmentioning

confidence: 99%

Gulf Cooperation Council states: On the brink of HBV elimination

Lazarus

Mark²,

Sanai

et al. 2021

Liver International

View full text Add to dashboard Cite

“…During the HBeAg-negative phase, treatment is recommended when alanine aminotransferase (ALT) is persistently or intermittently elevated above the upper limit of normal (ULN), the HBV DNA is over 2,000 IU/mL, and/or with significant fibrosis (for instance, METAVIR score F2-4). [ 2 3 ] In contrast, given the good long-term prognosis, periodic monitoring is recommended in patients with chronic HBV infection (”inactive carriers”). [ 2 3 ]…”

Section: Introductionmentioning

confidence: 99%

“…[ 2 3 ] In contrast, given the good long-term prognosis, periodic monitoring is recommended in patients with chronic HBV infection (”inactive carriers”). [ 2 3 ]…”

Section: Introductionmentioning

confidence: 99%

Lower prevalence of hepatic fibrosis in low viremic hepatitis B patients with fluctuating HBV DNA levels

Sanai¹,

Alhouthali²,

Alghamdi³

et al. 2022

Saudi J Gastroenterol

Self Cite

View full text Add to dashboard Cite

Background: In chronic hepatitis B virus (HBV) patients, fluctuations in HBV DNA serve as a “gray area” and impede the accurate identification of inactive carriers. We aimed to assess if such fluctuations impact the presence of significant hepatic fibrosis (Metavir F2-4) in chronic HBV patients. Methods: Consecutive, untreated HBeAg-negative carriers ( n = 234) with fluctuating HBV DNA ( n = 73) above or below a level of 2000 IU/mL were included and compared to those without fluctuations ( n = 161). Patients without fluctuating HBV DNA were further analyzed based on those with persistently low (<2,000 IU/mL, n = 137) and higher HBV DNA (2,000–20,000 IU/mL, n = 24). Hepatic fibrosis (assessed by transient elastography) was correlated with virologic and biochemical profiles. Results: The mean age of the overall cohort was 47.8 ± 11.1 years, of whom 107 (45.7%) were male. During a median of 60 months (interquartile range [IQR] 34–82) of follow-up, 73 (31.2%) patients had a mean of 1.6 ± 0.9 fluctuations in HBV DNA. The median time to the first fluctuation was at 14.5 (IQR 5.0–33.7) months. Patients with fluctuating viremia had higher log 10 qHBsAg (3.1 ± 0.8 vs. 2.7 ± 1.0, P = 0.022) and HBV DNA (3.4 ± 0.5 vs. 2.7 ± 0.8, P < 0.001) compared to those without fluctuations. Patients with fluctuant viremia were less likely to have F2-4 fibrosis (8.2%) compared to those without fluctuant viremia (18.2%, odds ratio [OR]: 0.407, 95% confidence interval [CI]: 0.161–1.030; P = 0.052). Males tended to have less fluctuation constituting 37.0% of patients with fluctuating HBV DNA ( P = 0.071). Fluctuations occurred more frequently in those with predominantly higher HBV DNA levels (26.0%) compared to those without fluctuations (14.9%; P = 0.030). Conclusions: Fluctuating HBV DNA levels occur frequently but are not associated with significant fibrosis. Minor fluctuations in HBV DNA levels are unlikely to be of clinical relevance.

show abstract

SASLT practice guidelines for the management of Hepatitis B virus – An update

Cited by 13 publications

References 72 publications

Application Effect and Accuracy Analysis of Electrochemiluminescence Immunoassay and Enzyme-Linked Immunosorbent Assay in the Serological Test of Hepatitis B Virus

Application Effect and Accuracy Analysis of Electrochemiluminescence Immunoassay and Enzyme-Linked Immunosorbent Assay in the Serological Test of Hepatitis B Virus

Gulf Cooperation Council states: On the brink of HBV elimination

Lower prevalence of hepatic fibrosis in low viremic hepatitis B patients with fluctuating HBV DNA levels

Contact Info

Product

Resources

About